{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:18:15Z","timestamp":1778577495975,"version":"3.51.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"The EORTC ENOQUA"},{"name":"EORTC Brain Tumor Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>AbstractAbstractAbstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The care of patients with brain tumors is a complex task that requires quality standards and quality assurance indicators. In the present study, several quality indicators were evaluated in routine clinical care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The EORTC Brain Tumor Group (BTG) developed quality indicators from published guidelines and tested them in 19 BTG sites across Europe. Each site extracted data from the files of 20 randomly selected glioblastoma patients diagnosed in 2018. Associations between quality indicators, site characteristics and median overall survival (mOS) were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 364 patient files were evaluated at 19 sites. Excellent compliance was observed in the documentation of neuropathology report with isocitrate dehydrogenase (IDH) status (92.0%), O6-methylguanine DNA methyltransferase promoter methylation (MGMT) status (78.0%), multidisciplinary case discussion (95.3 %), extent of resection (87.1%), and radiotherapy details (96.9%) as well as consent to chemotherapy (75.5%). Performance was not as good for early postoperative MRI (67.2%), psycho-oncological care (40.5%), avoiding antineoplastic therapy in the last weeks of life (63.1%) and early referral to palliative services (23.5%). Timely start of radiotherapy (P\u2009=\u2009.0153), the presence of a radiotherapy report in the medical record (P\u2009=\u2009.0077), and patient education on oral chemotherapy (P\u2009=\u2009.0002) were positively associated with mOS, while early referral to palliative care was associated with shorter mOS (P\u2009&amp;lt;\u2009.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The quality indicators tested in this research project performed with some variability between sites. Significant associations between individual quality indicators and mOS were observed. The proposed quality indicators should be validated prospectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/nop\/npaf103","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:12:49Z","timestamp":1760011969000},"page":"518-527","source":"Crossref","is-referenced-by-count":0,"title":["European neuro-oncology quality assessment (ENOQUA): A European organization for the research and treatment of cancer (EORTC) brain tumor group research project"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-2947","authenticated-orcid":false,"given":"Evangelia","family":"Razis","sequence":"first","affiliation":[{"name":"3rd Medical Oncology Department, Hygeia (Diagnosticon kai Therapeutikon Kentron Athenon UGEIA) Hospital , Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Gorlia","sequence":"additional","affiliation":[{"name":"EORTC Headquarters, Brussels,","place":["Belgium (T.G.)"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Daisne","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Leuven, Catholic University of Leuven, Leuven,","place":["Austria (J.F.D.)"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludo","family":"Vanopdenbosch","sequence":"additional","affiliation":[{"name":"Departments of Neurology, Oncology and Palliative Care, AZ Sint Jan Brugge , Brugge"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-214X","authenticated-orcid":false,"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich and University of Zurich , Zurich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian J","family":"Mair","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus Wolfram","family":"Gross","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiooncology, University Hospital Basel , Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Espeli","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale , Bellinzona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7288-8975","authenticated-orcid":false,"given":"Tomas","family":"Kazda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Research Center for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-5047","authenticated-orcid":false,"given":"Jordi","family":"Bruna","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Institut Catal\u00e0 d\u2018Oncologia l\u2018Hospitalet, Institut d\u2018Investigaci\u00f3 Biom\u00e8dica de Bellvitge (Oncobell Program), L\u2019Hospitalet de Llobregat , Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Di Cristofori","sequence":"additional","affiliation":[{"name":"Neurosurgery, Fondazione IRCCS San Gerardo dei Tintori , Monza"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-2132","authenticated-orcid":false,"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS , Padua"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egils","family":"Valeinis","sequence":"additional","affiliation":[{"name":"Neurosurgery Clinic, Pauls Stradins Clinical University Hospital Riga"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7998-9904","authenticated-orcid":false,"given":"Dieta","family":"Brandsma","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute , Amsterdam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Malmstrom","sequence":"additional","affiliation":[{"name":"Department of Geriatrics and Palliative Medicine and Division of Cell and Neurobiology, Department of Biomedical and Clinical Sciences, Link\u00f6ping University , Link\u00f6ping"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-495X","authenticated-orcid":false,"given":"Petter","family":"Brandal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital , Oslo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Azevedo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Instituto Portugues de Oncologia de Lisboa Francisco Gentil , Lisboa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naureen","family":"Keric","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Medical Center Mainz , Mainz"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5360-046X","authenticated-orcid":false,"given":"Philipp","family":"Lohmann","sequence":"additional","affiliation":[{"name":"Institute for Neuroscience and Medicine (INM-4), Research Center Juelich , Juelich"},{"name":"Department of Nuclear Medicine, University Hospital RWTH Aachen , Aachen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Vernadou","sequence":"additional","affiliation":[{"name":"3rd Medical Oncology Department, Hygeia (Diagnosticon kai Therapeutikon Kentron Athenon UGEIA) Hospital , Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitta Gertrud","family":"Baumert","sequence":"additional","affiliation":[{"name":"Institute of Radiation-Oncology, Cantonal Hospital Graubunden , Chur"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3647-5916","authenticated-orcid":false,"given":"Nicolaus","family":"Andratschke","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital of Zurich, University of Zurich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich and University of Zurich , Zurich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"de Vos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht , Utrecht"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hau","sequence":"additional","affiliation":[{"name":"Department of Neurology and Wilhelm Sander NeuroOncology Unit, University Hospital Regensburg , Regensburg"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"2026051204525995100_npaf103-B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of global incidence and mortality for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026051204525995100_npaf103-B2","first-page":"e8195","article-title":"Increasing incidence of glioblastoma multiforme in a well-defined population","volume":"12","author":"Grech","year":"2020","journal-title":"Cureus"},{"key":"2026051204525995100_npaf103-B3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026051204525995100_npaf103-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.03.016","article-title":"Next generation neuro-oncology","volume":"96","author":"Weller","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026051204525995100_npaf103-B5","year":"2019"},{"key":"2026051204525995100_npaf103-B6","year":"2014"},{"key":"2026051204525995100_npaf103-B7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/WNL.0000000000005251","article-title":"Quality improvement in neurology: neuro-oncology quality measurement set","volume":"90","author":"Jordan","year":"2018","journal-title":"Neurology"},{"key":"2026051204525995100_npaf103-B8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiologic response assessment in clinical glioblastoma trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"2026051204525995100_npaf103-B9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification for central nervous system tumors: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026051204525995100_npaf103-B10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1200\/JOP.2014.001556","article-title":"Improving the quality of care for patients diagnosed with glioma in the perioperative period","volume":"10","author":"Riblet","year":"2014","journal-title":"J Oncol Pract"},{"key":"2026051204525995100_npaf103-B11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-022-03971-3","article-title":"Quality indicators in neuro-oncology: review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey","volume":"157","author":"Vanhauwaert","year":"2022","journal-title":"J Neurooncol"},{"key":"2026051204525995100_npaf103-B12","doi-asserted-by":"crossref","first-page":"100438","DOI":"10.1016\/j.jcpo.2023.100438","article-title":"European Cancer Organization essential requirements for quality cancer care: adult glioma","volume":"38","author":"Bozzao","year":"2023","journal-title":"J Cancer Policy"},{"key":"2026051204525995100_npaf103-B13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.semradonc.2014.06.009","article-title":"Standardization and quality assurance in radiotherapy volumes for adults with high-grade gliomas","volume":"24","author":"Fogh","year":"2014","journal-title":"Semin Radiat Oncol"},{"key":"2026051204525995100_npaf103-B14","doi-asserted-by":"crossref","DOI":"10.1093\/nop\/npaf037","article-title":"Evaluating current quality indicators used in the care of adult patients with glioblastoma: a scoping review of the literature","author":"Shah","year":"2025","journal-title":"Neuro-Oncol Pract"},{"key":"2026051204525995100_npaf103-B15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/qshc.2004.011478","article-title":"Do clinical trials improve quality of care? A comparison of clinical processes and outcomes in patients in a clinical trial and similar patients outside a trial, with both groups treated according to a rigorous protocol","volume":"14","author":"West","year":"2005","journal-title":"Qual Saf Health Care"},{"key":"2026051204525995100_npaf103-B16","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/neuonc\/noy027","article-title":"The landscape of glioblastoma clinical trials: is it fit for purpose for the development of new therapies?","volume":"20","author":"Vanderbeek","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026051204525995100_npaf103-B17","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1200\/JCO.2005.05.948","article-title":"A method for measuring the quality of cancer care: the quality oncology practice initiative","volume":"23","author":"Neuss","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026051204525995100_npaf103-B18","doi-asserted-by":"crossref","DOI":"10.7249\/RB9219","volume-title":"Measuring the Quality of Cancer Care: The National Initiative for Cancer Care Quality (NICCQ)","author":"Hewitt","year":"2006"},{"key":"2026051204525995100_npaf103-B19","doi-asserted-by":"crossref","first-page":"e847","DOI":"10.1016\/j.wneu.2022.11.143","article-title":"Impact of palliative care on survival in glioblastoma: who receives palliative care?","volume":"170","author":"Pando","year":"2023","journal-title":"World Neurosurg"},{"key":"2026051204525995100_npaf103-B20","first-page":"299","article-title":"Trends and outcomes of early and late palliative care consultation in adult patients with glioblastoma: a retrospective SEER-Medicare study","volume":"9","author":"Wu","year":"2022","journal-title":"Neurooncol Pract"},{"key":"2026051204525995100_npaf103-B21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"2026051204525995100_npaf103-B22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JOP.2014.001206","article-title":"Welcoming the era of quality improvement in neuro-oncology","volume":"10","author":"Norden","year":"2014","journal-title":"J Oncol Pract"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npaf103\/64639405\/npaf103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/3\/518\/64639405\/npaf103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/3\/518\/64639405\/npaf103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:53:03Z","timestamp":1778575983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/13\/3\/518\/8283563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,11]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npaf103","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2025,10,11]]}}}